Skip to main content

We believe microbiome science has the power to revolutionize health—and transform lives.

We exist to accelerate progress—by helping deliver today’s most promising treatments, while laying the groundwork for tomorrow’s breakthroughs.

OpenBiome Foundation’s mission is to expand patient access to microbiome therapies and drive scientific discoveries that shape the future of health.

Through targeted investments, strategic collaborations, and open-access resources, we equip clinicians, scientists, and healthcare systems with tools to harness the microbiome’s full potential— creating a future where our work continues long after our mission is fulfilled. 

We Are OpenBiome Foundation

OpenBiome Foundation began with a bold belief: that the microbiome holds untapped power to transform human health. For over a decade, we saw that potential come to life—helping thousands of patients overcome Clostridioides difficile (C. diff) through access to safe, effective fecal microbiota transplantation (FMT). When regulatory changes forced us to stop delivering these treatments, it was a heartbreaking shift—not just for us, but for the patients who counted on them.

But our mission is far from over.

Our Goals

By 2030, OpenBiome Foundation will have:

Closed critical gaps in C. diff treatment, ensuring all patients have access to safe, effective, and widely available treatments.

Equipped clinicians, scientists, and healthcare systems with the knowledge, tools, and infrastructure to advance and deliver life-changing microbiome therapies.

Fueled scientific breakthroughs that not only redefined the role of the microbiome in human health but also paved the way for new microbiome-directed therapies.

Developed and shared high-impact resources that empowered the research community, accelerated the pace of discovery and enabled researchers to build on one another’s work.

Our Successes

In 2012, OpenBiome stepped up to meet a critical need—patients battling recurrent C. diff had few options and no safe, standardized access to FMT. So, we stepped in to bridge the gap.

Thought Leadership

Ideas

Letter from the CEO: The Road Ahead as the OpenBiome Foundation

Science in the Field: Dr. Walter Sandoval’s Mission to Map Rural Microbiomes in Paraguay

OpEd: The FDA must save the fecal transplant

Effectiveness and Safety of Fecal Microbiota Transplantation for Clostridioides Difficile Infection: Results From a 5344-Patient Cohort Study